Health and Healthcare

Baxter Split-Up, a Page From Abbott's Playbook

Baxter International Inc. (NYSE: BAX) is taking an activist investor role of its own. The health care company has announced that it is splitting itself into two separate companies, in what is expected to be a tax-free move. One business will be focused on biopharmaceuticals (biotech and pharmaceuticals) and the other company will be focused on its remaining medical products.

Baxter’s pharmaceutical business had sales of close to $6 billion in 2013. This unit has key products and a focus on hemophilia and blood therapies that treat immune deficiencies. It also includes burns and shock.

The other medical products business of Baxter had more than $9 billion in 2013 revenues. Its product portfolio is made up of intravenous and nutritional therapies, as well as surgical products, anesthesia products, kidney dialysis from Gambro AB, and drug delivery systems. This company will continue to be named Baxter International.

The company’s new management structure is described as follows:

Robert L. Parkinson, Jr., will serve as chairman and chief executive officer of the medical products company, which will retain the Baxter International name. Ludwig N. Hantson, Ph.D., who currently serves as president, BioScience, will be named chief executive officer of the new biopharmaceuticals company.

Investors will have to be patient here, as the split is not expected to be finished until the middle of 2015. If this sounds familiar, it is very similar to the Abbott Laboratories (NYSE: ABT) and AbbVie Inc. (NYSE: ABBV) break-up of 2013.

Baxter International shares are rising handily on the news. Thursday’s trading indications were up almost 10% at $76.60, which appears to be a new all-time high, versus its 52-week range of $62.80 to $74.60. Thomson Reuters had the Baxter consensus analyst price target up at $76.85, but that was before the split-up was announced.

The Average American Has No Idea How Much Money You Can Make Today (Sponsor)

The last few years made people forget how much banks and CD’s can pay. Meanwhile, interest rates have spiked and many can afford to pay you much more, but most are keeping yields low and hoping you won’t notice.

But there is good news. To win qualified customers, some accounts are paying almost 10x the national average! That’s an incredible way to keep your money safe and earn more at the same time. Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 3.80% with a Checking & Savings Account today Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

Click here to see how much more you could be earning on your savings today. It takes just a few minutes to open an account to make your money work for you.

 

Our top pick for high yield savings accounts includes other benefits as well. You can earn up to 4.00% with a Checking & Savings Account from Sofi. Sign up and get up to $300 with direct deposit. No account fees. FDIC Insured.

1 https://www.fdic.gov/national-rates-and-rate-caps

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.